Charles Robb
2018
In 2018, Charles Robb earned a total compensation of $2.8M as Chief Financial Officer and Secretary at Corcept Therapeutics, a 60% increase compared to previous year.
Compensation breakdown
| Bonus | $237,600 |
|---|---|
| Option Awards | $2,171,400 |
| Salary | $436,667 |
| Total | $2,845,667 |
Robb received $2.2M in option awards, accounting for 76% of the total pay in 2018.
Robb also received $237.6K in bonus and $436.7K in salary.
Rankings
In 2018, Charles Robb's compensation ranked 4,091st out of 14,244 executives tracked by ExecPay. In other words, Robb earned more than 71.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,091 out of 14,244 | 71st |
Division Manufacturing | 1,507 out of 5,765 | 74th |
Major group Chemicals And Allied Products | 537 out of 2,128 | 75th |
Industry group Drugs | 449 out of 1,817 | 75th |
Industry Pharmaceutical Preparations | 346 out of 1,391 | 75th |
Source: SEC filing on April 27, 2020.
Robb's colleagues
We found four more compensation records of executives who worked with Charles Robb at Corcept Therapeutics in 2018.
News
Corcept Therapeutics CEO Joseph Belanoff's 2021 pay jumps 91% to $11M
April 25, 2022
Corcept Therapeutics CEO Joseph Belanoff's 2020 pay rises 16% to $5.8M
April 22, 2021
Corcept Therapeutics CEO Joseph Belanoff's 2019 pay falls 21% to $5M
April 27, 2020
Corcept Therapeutics CEO Joseph Belanoff's 2018 pay jumps 48% to $6.3M
April 24, 2019